: News

Pain management is becoming a more and more important theme among the scientific community in the different medical disciplines.

For this reason, IBSA will be present at the EFIC Congress “Pain in Europe VIII” (http://www1.kenes.com/efic/), which will be held in Florence from 9 to 12 October, with a satellite symposium and a booth.

The symposium, scheduled for Friday, October 11, 12:15-13:45 (Hall E, Padiglione Spadolini) will be entirely dedicated to the pain, both in acute and chronic pathologies, and to the need of identifying the most appropriate therapeutic approach for a tailor-made treatment (Program).

IBSA’s portfolio dedicated to the pain management will be presented at the booth during the congress.

This includes Sinovial^®, Flector^® and the new and innovative injectable formulation of diclofenac whose peculiarity is the reduced volume (1 ml) which allows the subcutaneous administration.

IBSA continues to support and be present at the EULAR Congress, European League Against Rheumatism  (www.eular.org) which will be held in Madrid from 12 to 15 June.

The main scientific activity is scheduled for Thursday, June 13, 8:15 to 9:45 (room Retiro), with a satellite symposium focused on the GAGs therapy ("GlycosAminoGlycans therapy")  in OA management (Program)

Under this concept, experts in the field will highlight the main characteristics of the most relevant glycosaminoglycans (ie chondroitin sulfate and hyaluronic acid), from the mechanisms of action to the recent clinical evidences of these compounds in the OA management. 

Other activities are related to IBSA’s presence in the exhibition area with a booth where the complete Company’s portfolio in the OA and pain area, recently enlarged with the new and innovative 1 ml injectable formulation of diclofenac, will be presented to the medical community

IBSA will attend the 28th Annual EAU Congress (http://www.eaumilan2013.org/) with a Satellite Symposium scheduled on Saturday, March 16th, from 18.00 to 19.30 (Mi.Co – Milano Congressi, room Amber 1+2 - program). At this occasion, a special focus will be made on the latest clinical results of the association of sodium hyaluronate and chondroitin sulfate (Ialuril®) in the treatment of cystitis of various origins.
In addition, we will also have a stand in the exhibition hall (F01 – Mi.Co South Wing, Level 0) where we’ll be glad to meet our partners and new contacts interested in our product in the urology field.

IBSA will attend the 21st Congress of the European Academy of Dermatology and Venereology (EADV), entitled “Skin is Vital”, that will be held in Prague (September, 27th - 30th)

(http://www.eadvprague2012.org/) with an exhibition booth dedicated to its dermatology pipeline.

 IBSA products for wound healing (Ialuset^®-Ialuset Plus^®), skin rejuvenation (Aliaxin^®-Viscoderm^®) and for the treatment of psoriasis and other dermatologic diseases (Betesil^®) will be presented.

 This will be also the occasion to dedicate a special focus on Hyaluronic acid, which represents one of the main components of IBSA dermatology line, and to provide details on the whole production process throught a technical description, simplified by a funny animation.

EADV 2012, Prague, Czech Republic, September 26th to 30th 
IBSA will be attending the congress with a stand area in the exhibition hall. Any possible satellite session will be confirmed at the later stage during the year.

ETA 2012, Pisa, Italy, September 8th to 12th 
The date and programme of the symposium will be available soon.